Participated · Seed · Nov 2025

Glitch is a Dublin-based startup founded by Aisling Browne and Kingsley Kelly that aims to make digital advertising simpler and more effective for business-to-business marketers. Its cloud platform leverages artificial intelligence to automate labor-intensive steps such as campaign creation, audience targeting, budget allocation, and in-flight optimization. The software also surfaces actionable insights on high-performing content and keywords, enabling small marketing teams to run sophisticated ad programs without the complexity of legacy ad-tech tools. Operating from Dogpatch Labs, the company positions itself at the intersection of AdTech, marketing automation, and AI. With a recently secured seed round, Glitch plans to expand its commercial teams, push into new international markets, and roll out additional product features. The fresh capital provides the financial runway to accelerate go-to-market efforts and product development, though no revenue or user metrics have yet been disclosed.

Participated · Seed · Oct 2025

NeuroBell develops LUNA, a battery-powered, WiFi-connected neonatal electroencephalogram (EEG) system that provides bedside, clinical-grade brain monitoring. LUNA features an eight-channel EEG amplifier, 10-20 EEG electrode placement for neonates, a two-button setup to begin recording, and continuous impedance checks. The system offers automated neonatal seizure detection to support quicker identification of seizures and decision-making by NICU staff. NeuroBell says LUNA enables quick setup and recording for NICU teams regardless of size or location and supports continuous monitoring at the bedside. The company is based in Cork, Ireland, and is anticipating FDA clearance in the coming months. NeuroBell raised $5.5 million in a financing led by Elkstone, with participation from Parkview Health and existing investors to support clinical deployment and U.S. market entry.

Participated · Seed · Jul 2025

Movetru’s flagship product is a wearable device paired with an AI-powered app that provides real-time biomechanical insights for on-field, gym and rehab use. The system is designed to give coaches and clinicians actionable movement data to assess performance and injury risk. The product is already being used by professional and amateur sports organisations across the UK and Ireland, with strong early results and positive feedback. Founder and CEO Naomi McGregor built the company following a personal injury experience and holds a Masters in Product Design Engineering. Movetru recently closed €1.4M in Pre-Seed funding to scale operations and accelerate a wider commercial rollout. Athletes and coaches can book on-field screenings and pre-order devices via the company website as part of its commercialization push.

Led · Equity · Mar 2024

Quantmatix develops a proprietary predictive analytics algorithm that uses big data, artificial intelligence and machine learning to forecast prices and market performance across equities, fixed income, FX, crypto and commodities. Its AI-assisted market-timing tool offers slow-moving persistent scores, actionable trading signals and dynamic market support and resistance levels. Tested against major indices, the algorithm outperformed the Stoxx 50 by 38.3%, the S&P by 14.0%, Stoxx Europe 600 by 48.0% and the FTSE 100 by 31.7% over the most recent six-year period. The company is preparing to launch a Software-as-a-Service product targeted at family offices and professional investors. New funding will be used to expand sales and marketing in the US, the Middle East and Asia, support additional hires to bring headcount to 20, and further invest in AI and big data. Quantmatix reported equity of €296,700 at the end of 2022 and a loss of €504,900 for that year.

Participated · Equity · Dec 2023

SymPhysis Medical is building Releaze, a port-style drainage system that combines a safety-valve catheter with a compact external hub, allowing patients and carers to relieve malignant pleural effusion at home instead of enduring repeated hospital procedures. The condition, which causes painful fluid build-up in the chest, affects more than 150,000 people annually in the United States, and Releaze aims to improve comfort and reduce hospital visits for these patients. Headquartered in Galway, the company has worked closely with Irish clinicians, nurses, patients and carers to design and refine the device. With the new U.S. grant, SymPhysis Medical will open its first American base in Rhode Island, advance testing and move toward its initial FDA regulatory clearance. The firm also plans to build partnerships across New England’s life-sciences cluster while continuing to expand engineering and operations in Ireland. To date, the company has raised over €4 million from Irish and European investors and health-innovation programmes, adding to the latest U.S. public-sector funding. These combined resources provide the runway to progress Releaze toward early international commercialisation.